{"id":"W3096052786","doi":"10.1182/blood-2020-139438","title":"Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Daratumumab; Bortezomib; Dexamethasone; Medicine; Cyclophosphamide; AL amyloidosis; Internal medicine; Amyloidosis; Andromeda; Melphalan; Oncology; Multiple myeloma; Immunology; Chemotherapy; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002343282,0.0006693661,0.001017326,0.000306558,0.0003503993,0.0009541793,0.0004338912,0.0006539259,0.0008341229],"category_scores_gemma":[0.001540208,0.0002108883,0.00220979,0.0005283268,0.0003189496,0.0004796933,0.0005409492,0.001042184,0.0001817237],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005468006,"about_ca_system_score_gemma":0.0005144638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001063275,"about_ca_topic_score_gemma":0.001871798,"domain_scores_codex":[0.9990983,0.0004901463,0.00007016513,0.0001304629,0.0001227185,0.00008833118],"domain_scores_gemma":[0.9984747,0.0002784733,0.000681069,0.00005397647,0.0001191991,0.000392711],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1706894,0.005347631,0.7606381,0.0009700186,0.008474252,0.0002192369,0.0002763135,0.001619163,0.001735599,0.0001607153,0.004124522,0.045745],"study_design_scores_gemma":[0.04606358,0.02437015,0.9203601,0.0001843387,0.003793908,0.0004858398,0.0001979481,0.001399645,0.0003798366,0.0001889843,0.002520125,0.0000556274],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918672,0.005045174,0.00009706643,0.0003034213,0.00005977615,0.0001751231,0.001632624,0.00001042213,0.0008090663],"genre_scores_gemma":[0.9948395,0.001187667,0.0002613036,0.0003927072,0.0001108757,0.0002157319,0.002774741,0.00000346067,0.00021404],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002343282,"threshold_uncertainty_score":0.01239258,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01709534942048417,"score_gpt":0.2699801047860994,"score_spread":0.2528847553656152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}